Povorcitinib, with the CAS number 1637677-22-5, is a small molecule that functions as a selective inhibitor of Janus kinase (JAK) enzymes, particularly JAK1. This compound is primarily investigated for its potential therapeutic applications in autoimmune diseases and inflammatory conditions, such as psoriasis and rheumatoid arthritis. Povorcitinib exhibits a favorable pharmacokinetic profile, allowing for oral administration, and demonstrates a good balance between efficacy and safety in clinical trials. Its mechanism of action involves the modulation of cytokine signaling pathways, which are crucial in the pathophysiology of various inflammatory disorders. The compound's chemical structure features specific functional groups that contribute to its biological activity and selectivity for JAK1 over other JAK family members. As research continues, povorcitinib may offer new avenues for treatment in conditions where traditional therapies have limitations. However, ongoing studies are essential to fully understand its long-term effects and potential side effects in diverse patient populations.

povorcitinib

1637677-22-5: Povorcitinib, with the CAS number 1637677-22-5, is a small molecule that functions as a selective inhibitor of Janus kinase (JAK) enzymes, particularly JAK1. This compound is primarily investigated for its potential therapeutic applications in autoimmune diseases and inflammatory conditions, such as psoriasis and rheumatoid arthritis. Povorcitinib exhibits a favorable pharmacokinetic profile, allowing for oral administration, and demonstrates a good balance between efficacy and safety in clinical trials. Its mechanism of action involves the modulation of cytokine signaling pathways, which are crucial in the pathophysiology of various inflammatory disorders. The compound's chemical structure features specific functional groups that contribute to its biological activity and selectivity for JAK1 over other JAK family members. As research continues, povorcitinib may offer new avenues for treatment in conditions where traditional therapies have limitations. However, ongoing studies are essential to fully understand its long-term effects and potential side effects in diverse patient populations.

<p>Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).</p>

CAS 1637677-22-5

povorcitinib

Povorcitinib

Ref: TM-T39113